Adagene Inc - ADR Stock

$1.98

0.77% day before yesterday

Nasdaq, Dec 27, 09:17 pm CET

ISIN

US0053291078

Symbol

ADAG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Adagene Inc - ADR Stock price

$1.96

-28.03 93.46% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.00 0.00%

ISIN

US0053291078

Symbol

ADAG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$86.77m
Enterprise Value	$11.89m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	14.33
P/S ratio (TTM) P/S ratio	104.54
P/B ratio (TTM) P/B ratio	1.53
Revenue growth (TTM) Revenue growth	-96.36%
Revenue (TTM) Revenue	$830.00k
EBIT (operating result TTM) EBIT	$-37.46m
EPS (TTM) EPS	$-0.73
P/S forward	4.57
EV/Sales forward	0.63
Short interest	0.03%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Adagene Inc - ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Adagene Inc - ADR:

1x Hold

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Adagene Inc - ADR:

Hold

100%

Analyst Estimates with Stock Price Targets

Financial data from Adagene Inc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	0.83 0.83	96% 96% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.89 7.89	18% 18% 951%
- Research and Development Expense	30 30	48% 48% 3,664%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-37 -37	18% 18% -4,514%
Net Profit	-32 -32	15% 15% -3,876%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adagene Inc - ADR Stock News

Neutral

GlobeNewsWire

●

about 2 months ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -

Neutral

GlobeNewsWire

●

3 months ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.

Neutral

GlobeNewsWire

●

3 months ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab -

More Adagene Inc - ADR News

Company Profile

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Head office	Cayman Islands
CEO	Peizhi Luo
Employees	174
Founded	2011
Website	www.adagene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now